DNMT1 and acute myeloid leukemia: Two DNMT inhibitors (azacytidine and decitabine) cxvdv have been approved for the treatment of hematologic malignancies, particularly AML and MDS.494–496 These cytosine analogs can incorporate into the DNA or RNA backbone to replace C-5 of cytosine with N-5 and interfere with the methylation as well as induce DNMTs degradation.